Bahrain, Canada and Lebanon Pharmaceuticals and Healthcare Report Q2 2016; New Report Launched

Bahrain's government will continue in its attempts to attract investments and expand domestic pharmaceutical manufacturing. Although there will be an expansion of local drug production, foreign drugmakers will continue to view Bahrain as an unattractive option for expansion. Instead, these firms will opt to develop their manufacturing capabilities in the larger regional markets of Saudi Arabia and the United Arab Emirates.

Headline Expenditure Projections

• Pharmaceuticals: BHD131mn (USD347mn) in 2015 to BHD140mn (USD372mn) in 2016; +7.2% in both local currency and US dollar terms. Forecast unchanged from last quarter.
• Healthcare: BHD635mn (USD1.68bn) in 2015 to BHD688mn (USD1.82bn) in 2016; +8.4% in both local currency and US dollar terms. Forecast in line with last quarter.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/bahrain-pharmaceuticals-and-healthcare-report-q2-2016

Canada is a significant manufacturing base for pharmaceutical companies as well as a market in its own right. Despite the expanding implementation of cost-containment reforms and rising uptake of lower value generic drugs, the effects of these trends will be mitigated by rising demand for and consumption of high volumes of prescriptions, particularly high value personalised medicines.

Headline Expenditure Projections

• Pharmaceuticals: CAD23.06bn (USD18.04bn) in 2015 to CAD23.52bn (USD17.42bn) in 2016; +2.0% in local currency terms and -3.4% in US dollar terms.
• Healthcare: CAD217.54bn (USD170.13bn) in 2015 to CAD225.19bn (USD166.81bn) in 2016; +3.5% in local currency terms and -2.0% in US dollar terms.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/canada-pharmaceuticals-and-healthcare-report-q2-2016

We hold a cautiously optimistic outlook for Lebanon's pharmaceutical market over the coming years. The government's focus on improving healthcare access across the country coupled with a rising disease burden and relatively high per capita spending will drive the demand of high-value prescription medicines. However, the unprecedented influx of refugees escaping war-torn Syria, emergence of Islamic State violence and political stagnation pose significant downside risks to our forecast.

Headline Expenditure Projections

• Pharmaceuticals: LBP2.46trn (USD1.63bn) in 2015 to LBP2.63trn (USD1.75bn) in 2016; +6.9% in local currency and +7.1% in US dollar terms. Forecast inline with last quarter.
• Healthcare: LBP5.41trn (USD3.59bn) in 2015 to LBP5.89trn (USD3.91bn) in 2016; +8.7% in local currency and +8.9% in US dollar terms. Forecast inline with last quarter.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/lebanon-pharmaceuticals-and-healthcare-report-q2-2016